Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5316-5322

  Gordon, N C ^a   Png, K ^a   Wareham, D W ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 78649646001     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00922-10     Document Type: Article

References (40)

1. Andrews, J. M., for the BSAC Working Party on Susceptibility Testing. 2009. BSAC standardized disc susceptibility testing method (version 8). J. Antimicrob. Chemother. 64:454-489.
2. Bonapace, C. R., R. L. White, L. V. Friedrich, and J. A. Bosso. 2000. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods. Diagn. Microbiol. Infect. Dis. 38:43-50.
3. Boucher, H. W., G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spelberg, and J. Bartlett. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
4. Carlone, G. M., M. L. Thomas, H. S. Rumschlag, and F. O. Sottnek. 1986. Rapid microprocedure for isolating detergent-insoluble outer membrane proteins from Haemophilus species. J. Clin. Microbiol. 24:330-332.
5. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement, CLSI document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Coelho, J. M., J. F. Turton, M. E. Kaufmann, J. Glover, N. Woodford, M. Warner, M. F. Palepou, R. Pike, T. L. Pitt, B. C. Patel, and D. M. Livermore. 2006. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J. Clin. Microbiol. 44:3623-3627.
7. Eliopoulos, G. M., and R. C. Moellering. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, MD.
8. European Committee on Antimicrobial Susceptibility Testing. 2010. Breakpoint table for interpretation of MICs and zone diameters, version 1.1. http://www.eucast.org/clinical-breakpoints/.
9. Falagas, M. E., and S. K. Kasiakou. 2005. Colistin: the revival of the polymyxins for the management of multi-drug resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341.
10. Falagas, M. E., P. K. Koletsi, and I. A. Bliziotis. 2006. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol. 55:1619-1629.
11. Hawley, J. S., C. K. Murray, and J. H. Jorgensen. 2008. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 52:351-352.
12. Higgins, P. G., M. Lehmann, and H. Seifert. 2010. Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 35:305.
13. Ko, K. S., J. Y. Suh, K. T. Kwon, S. I. Jung, K. H. Park, C. I. Kang, D. R. Chung, K. R. Peck, and J. H. Song. 2007. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 60:1163-1167.
14. Kroeger, L. A., L. B. Hovde, I. F. Mitropoulos, J. Schafer, and J. C. Rotschafer. 2007. Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 51:3431-3433.
15. Lam, C., J. Hildebrandt, E. Schütze, and A. Wenzel. 1986. Membrane-disorganising property of polymyxin B nonapeptide. J. Antimicrob. Chemother. 18:9-15.
16. Li, J., R. L. Nation, R. W. Milne, J. D. Turnidge, and K. Coulthard. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25.
17. Li, J., C. R. Rayner, R. L. Nation, R. J. Owen, D. Spelman, K. E. Tan, and L. Liolios. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50:2946-2950.
18. Livermore, D. M., R. L. Hill, H. Thomson, A. Charlett, J. F. Turton, R. Pike, B. C. Patel, R. Manuel, S. Gillespie, I. Balakrishnan, S. P. Barrett, N. Cumberland, M. Twagira, and the C-MRAB Study Group. 2010. Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. Int. J. Antimicrob. Agents 35:19-24.
19. Lo-Ten-Foe, J. R., A. M. de Smet, B. M. Diederen, J. A. Kluytmans, and P. H. van Keulen. 2007. Comparative evaluation of the VITEK 2, disk diffusion, Etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob. Agents Chemother. 51:3726-3730.
20. Markou, N., S. L. Markantonis, E. Dimitrakis, D. Panidis, E. Boutzouka, S. Karatzas, P. Rafailidis, H. Apostolakos, and G. Baltopoulos. 2008. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin. Ther. 30:143-151.
21. Milne, K. E., and I. M. Gould. 2010. Combination of testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J. Antimicrob. Chemother. 65:82-90.
22. Moriarty, F., S. Elborn, and M. Tunney. 2005. Development of a rapid colorimetric time-kill assay for determining the in vitro activity of ceftazidime and tobramycin in combination against Pseudomonas aeruginosa. J. Microbiol. Methods 61:171-179.
23. Nicolosi, D., M. Scalia, V. M. Nicolosi, and R. Pignatello. 2010. Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria. Int. J. Antimicrob. Agents 35:553-558.
24. Pachón-Ibáñez, M. E., F. Docobo-Pérez, R. López-Rojas, J. Domínguez-Herrera, M. E. Jiménez-Mejias, A. García-Curiel, C. Pichardo, L. Jiménez, and J. Pachón. 2010. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 54:1165-1172.
25. Pea, F., M. Furlanut, C. Negri, F. Pavan, M. Crapis, F. Cristini, and P. Viale. 2009. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob. Agents Chemother. 53:1863-1867.
26. Peleg, A. Y., H. Seifert, and D. L. Paterson. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
27. Petrosillo, N., E. Ioannidou, and M. E. Falagas. 2008. Colistin monotherapy vs combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 14:816-827.
28. Rodriguez, C. H., K. Bombicino, G. Granados, M. Nastro, C. Vay, and A. Famiglietti. 2009. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn. Microbiol. Infect. Dis. 65:188-191.
29. Shlaes, D. M., J. H. Shlaes, J. Davies, and R. Williamson. 1989. Escherichia coli susceptible to glycopeptide antibiotics. Antimicrob. Agents Chemother. 33:192-197.
30. Soon, R. L., R. L. Nation, P. G. Hartley, I. Larson, and J. Li. 2009. Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment. Antimicrob. Agents Chemother. 53:4979-4986.
31. Tan, T. Y., L. S. Ng, E. Tan, and G. Huang. 2007. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J. Antimicrob. Chemother. 60:421-423.
32. Tripodi, M. F., E. Durante-Mangoni, R. Fortunato, R. Utili, and R. Zarrilli. 2007. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int. J. Antimicrob. Agents 30:537-540.
33. Turton, J. F., M. E. Kaufmann, M. J. Gill, R. Pike, P. T. Scott, J. Fishbain, D. Craft, G. Deye, S. Riddell, L. E. Lindler, and T. L. Pitt. 2006. Comparison of Acinetobacter baumannii isolates from the United Kingdom and the United States that were associated with repatriated casualties of the Iraq conflict. J. Clin. Microbiol. 44:2630-2634.
34. Turton, J. F., S. N. Gabriel, C. Valderrey, M. E. Kaufmann, and T. L. Pitt. 2007. Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of Acinetobacter baumannii. Clin. Microbiol. Infect. 13:807-815.
35. OXA-51-like carbapenemase gene intrinsic to this species. J. Clin. Microbiol. 44:2974-2976.
36. Vaara, M. 1992. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 56:395-411.
37. Vaara, M., O. Siikanen, J. Apajalahti, J. Fox, N. Frimodt-Møller, H. He, A. Poudyal, J. Li, R. L. Nation, and T. Vaara. 2010. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob. Agents Chemother. 54:3341-3346.
38. Wareham, D. W., and D. C. Bean. 2006. In vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob. 5:10.
39. Wareham, D. W., D. C. Bean, P. Khanna, E. M. Hennessy, D. Krahe, A. Ely, and M. Millar. 2008. Bloodstream infection due to Acinetobacter spp.: epidemiology, risk factors and impact of multi-drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. 27:607-612.
40. Woodford, N., M. J. Ellington, J. M. Coelho, J. F. Turton, M. E. Ward, S. Brown, S. G. Amyes, and D. M. Livermore. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 27:351-353.